Custopharm Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CUSTOPHARM INC, and when can generic versions of CUSTOPHARM INC drugs launch?
CUSTOPHARM INC has ten approved drugs.
There is one US patent protecting CUSTOPHARM INC drugs.
There is one patent family member on CUSTOPHARM INC drugs in one country and sixty-three supplementary protection certificates in eight countries.
Summary for Custopharm Inc
| International Patents: | 1 |
| US Patents: | 1 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 10 |
Drugs and US Patents for Custopharm Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Custopharm Inc | LEVOTHYROXINE SODIUM | levothyroxine sodium | SOLUTION;INTRAVENOUS | 214253-001 | May 17, 2021 | RX | Yes | Yes | 11,154,498 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Custopharm Inc | FLUDARABINE PHOSPHATE | fludarabine phosphate | INJECTABLE;INJECTION | 076349-001 | Aug 28, 2003 | AP | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| Custopharm Inc | GANCICLOVIR SODIUM | ganciclovir sodium | INJECTABLE;INJECTION | 212001-001 | Jun 20, 2019 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| Custopharm Inc | DICYCLOMINE HYDROCHLORIDE | dicyclomine hydrochloride | INJECTABLE;INJECTION | 210788-001 | Feb 11, 2019 | AP | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| Custopharm Inc | ACETAMINOPHEN | acetaminophen | SOLUTION;INTRAVENOUS | 202605-001 | Jun 13, 2016 | AP | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CUSTOPHARM INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
International Patents for Custopharm Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2017013591 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Custopharm Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0957929 | SPC/GB06/021 | United Kingdom | See Plans and Pricing | PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201 |
| 0480717 | 98C0022 | France | See Plans and Pricing | PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825 |
| 2822954 | 1890030-8 | Sweden | See Plans and Pricing | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625 |
| 2203431 | 92666 | Luxembourg | See Plans and Pricing | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
| 1758590 | LUC00029 | Luxembourg | See Plans and Pricing | PRODUCT NAME: SEL DE SODIUM D'ACIDE DEOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: IS/1/16/071/01 20170401 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
